IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer

June 20, 2019

Applied Clinical Trials

Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.  

To learn more about their findings, click here.

Related Content:

News